While earlier clinical trials of HDAC inhibitors show potential clinical benefit for patients with breast cancer [164], the role of HDAC inhibitors/degraders in immune modulation may provide a unique opportunity for some of those specific inhibitors/degraders—which have sufficient therapeutic windows and limited toxicity—to sensitize some solid cancers for ICI-based therapy. Here, HDAC9 is linked to breast cancer.